Table 2 Treatment characteristics
From: Radiation field size and dose determine oncologic outcome in esophageal cancer
Treatment characteristics | Pre-CRT (n = 25) | Def-CRT group (n = 49) | P value | ||
|---|---|---|---|---|---|
n | (%) | n | (%) | ||
Radiation planning | |||||
 Conventional (2D) | 10 | 40 | 20 | 41 | 0.95 |
 Conformal (3D) | 15 | 60 | 29 | 59 | |
Chemotherapy regimes | |||||
 Cisplatin + infusional 5-FU | 5 | 20 | 10 | 20 | 0.7 |
 Weekly cisplatin | 7 | 28 | 11 | 22 | |
 Weekly cisplatin + oral UFT | 8 | 32 | 16 | 33 | |
 Weekly cisplatin + paclitaxel | 3 | 12 | 7 | 14 | |
 Paclitaxel + 5-FU | 1 | 4 | 2 | 5 | |
 Weekly cisplatin + capecitabine | 1 | 4 | 3 | 6 | |
Radiation dose (cGy) | |||||
 4000–5000 | 25 | 100 | 39 | 78 | 0.01 |
 5001–6000 | 0 | 0 | 11 | 22 | |